{"entity":{"id":"nct05688280","kind":"trial","name":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","aka":[],"tldr":"A phase 1/2 trial of 1.0% IP-001 for Injection in colorectal cancer, non-small-cell lung cancer and sarcomas, run by Immunophotonics, Inc., active and no longer recruiting.","summary":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS is a phase 1/2 interventional study registered as NCT05688280 by Immunophotonics, Inc., with 42 participants enrolled, started 2022-11-29 and due to reach its primary completion in 2025-02. Interventions recorded: 1.0% IP-001 for Injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05688280","url":"https://clinicaltrials.gov/study/NCT05688280"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","nsclc","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05688280","phase":"1/2","setting":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients","sponsor":"Immunophotonics, Inc.","enrolled":42,"outcomes":[]},"route":"/trials/nct05688280/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}]}}